Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Masahiko Ohtsuki is active.

Publication


Featured researches published by Masahiko Ohtsuki.


Journal of Immunology | 2003

TRAIL-R2 (DR5) Mediates Apoptosis of Synovial Fibroblasts in Rheumatoid Arthritis

Kimihisa Ichikawa; Weimin Liu; Martin Fleck; Huang-Ge Zhang; Limin Zhao; Toshiaki Ohtsuka; Zheng Wang; Di Liu; John D. Mountz; Masahiko Ohtsuki; William J. Koopman; Robert P. Kimberly; Tong Zhou

TRAIL has been proposed as an anti-inflammatory cytokine in animal models of rheumatoid arthritis (RA). Using two agonistic mAbs specific for TRAIL-R1 (DR4) and TRAIL-R2 (DR5), we examined the expression and function of these death receptors in RA synovial fibroblast cells. The synovial tissues and primary synovial fibroblast cells isolated from patients with RA, but not those isolated from patients with osteoarthritis, selectively expressed high levels of cell surface DR5 and were highly susceptible to anti-DR5 Ab (TRA-8)-mediated apoptosis. In contrast, RA synoviocytes did not show increased expression of TRAIL-R1 (DR4), nor was there any difference in expression of Fas between RA and osteoarthritis synovial cells. In vitro TRA-8 induced apoptosis of RA synovial cells and inhibited production of matrix metalloproteinases induced by pro-inflammatory cytokines. In vivo TRA-8 effectively inhibited hypercellularity of a SV40-transformed RA synovial cell line and completely prevented bone erosion and cartilage destruction induced by these cells. These results indicate that increased DR5 expression and susceptibility to DR5-mediated apoptosis are characteristic of the proliferating synovial cells in RA. As highly proliferative transformed-appearing RA synovial cells play a crucial role in bone erosion and cartilage destruction in RA, the specific targeting of DR5 on RA synovial cells with an agonistic anti-DR5 Ab may be a potential therapy for RA.


Microbiology and Immunology | 2007

Caspase‐Independent Cell Death by Fas Ligation in Human Thymus‐Derived T Cell Line, HPB‐ALL Cells

Junichi Nakayama; Masahiko Ohtsuki; Tomiichiro Oda

In HPB‐ALL cells, a human thymus‐derived T‐cell line, Fas (CD95)‐mediated cell death was inhibited by about only 50% as a result of treatment with an amount of benzyloxycarbonyl‐Val‐Ala‐Asp‐(O‐methyl)‐CH2F (zVAD‐fmk) sufficient to block the caspase activity. Fas‐mediated caspase‐independent cell death was not observed in other lymphoblast cell lines or mouse activated splenocytes, but this type of cell death was observed in mouse and rat thymocytes, the same as for HPB‐ALL cells. This suggests that Fas‐mediated caspase‐independent cell death is a common feature in thymocytes. The signaling pathway of caspase‐independent cell death has not yet been fully elucidated. In HPB‐ALL cells, DNA fragmentation, one of the features of apoptotic cells, did not occur in the caspase‐independent cell death after Fas ligation. On the other hand, this type of cell death and the surface exposure of phosphatidylserine were recovered by pretreatment with geldanamycin, which brought about a decrease in receptor interacting protein (RIP) kinase expression. These results suggested that HPB‐ALL cells have a caspase‐independent RIP kinase‐dependent pathway for Fas ligation.


The Journal of Allergy and Clinical Immunology | 2001

Preclinical evaluation of an immunotherapeutic peptide comprising 7 T-cell determinants of Cry j 1 and Cry j 2, the major Japanese cedar pollen allergens

Kazuki Hirahara; Toru Tatsuta; Toshiro Takatori; Masahiko Ohtsuki; Hideyo Kirinaka; Junko Kawaguchi; Nobufusa Serizawa; Yoshifumi Taniguchi; Saburo Saito; Masahiro Sakaguchi; Sakae Inouye; Akio Shiraishi


International Immunology | 2000

A novel murine anti-human Fas mAb which mitigates lymphadenopathy without hepatotoxicity.

Kimihisa Ichikawa; Hiroko Yoshida-Kato; Masahiko Ohtsuki; Jun Ohsumi; Junko Yamaguchi; Shu Takahashi; Yoshiro Tani; Mayumi Watanabe; Akio Shiraishi; Kusuki Nishioka; Shin Yonehara; Nobufusa Serizawa


Archive | 2000

Anti-Fas antibodies

Nobufusa Serizawa; Kimihisa Ichikawa; Jun Ohsumi; Masahiko Ohtsuki; Hideyuki Haruyama; Tohru Takahashi; Hiroko Yoshida; Akio Shiraishi; Shin Yonehara


Arthritis & Rheumatism | 2003

Suppression of osteoclastogenesis in rheumatoid arthritis by induction of apoptosis in activated CD4+ T cells.

Yukie Ogawa; Masahiko Ohtsuki; Miwa Uzuki; Takashi Sawai; Yoshiko Onozawa; Junichi Nakayama; Akiko Yonemura; Tomoatsu Kimura; Hiroaki Matsuno


The Journal of Rheumatology | 2001

Therapeutic effect of anti-Fas antibody on a collagen induced arthritis model.

Yukie Ogawa; Harumi Kuwahara; Tomoko Kimura; Yoshio Tani; Shin Yonehara; Akio Shiraishi; Masahiko Ohtsuki


International Immunology | 2006

A humanized anti-human Fas antibody, R-125224, induces apoptosis in type I activated lymphocytes but not in type II cells

Junichi Nakayama; Yukie Ogawa; Yasushi Yoshigae; Yoshiko Onozawa; Akiko Yonemura; Motoko Saito; Kimihisa Ichikawa; Takashi Yamoto; Tomoaki Komai; Toru Tatsuta; Masahiko Ohtsuki


Clinical Immunology | 2001

Therapeutic effect of novel anti-human Fas antibody HFE7A on graft-versus-host disease model

Harumi Kuwahara; Yoshio Tani; Yukie Ogawa; Yasuhiro Takaichi; Akio Shiraishi; Masahiko Ohtsuki


Life Sciences | 2007

Tissue distribution of humanized anti-human Fas monoclonal antibody (R-125224) based on fas antigen–antibody reaction in collagen-induced arthritis monkeys

Motoko Saito; Yasushi Yoshigae; Junichi Nakayama; Yukie Ogawa; Masahiko Ohtsuki; Atsushi Kurihara; Toshihiko Ikeda

Collaboration


Dive into the Masahiko Ohtsuki's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Akio Shiraishi

University of Alabama at Birmingham

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Tohru Takahashi

Kansai Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Toshihiko Ikeda

Yokohama College of Pharmacy

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge